PT Medikaloka Hermina (HEAL) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
10 Aug, 2026Executive summary
Operates 53 hospitals with 9,019 beds and over 3,700 doctors as of June 30, 2026, making it the largest listed hospital group in Indonesia.
Net revenues for the six months ended June 30, 2026, reached Rp3,609,409 million, up 6.5% year-over-year from Rp3,388,561 million in 2025.
Net income for the period was Rp249,026 million, a decrease from Rp284,308 million in the prior year.
Maintains a unique doctor partnership model, aligning clinical and business goals to attract and retain top talent.
Focuses on women and children care, while expanding advanced specialties and Centers of Excellence.
Financial highlights
Total revenue for 6M26 reached IDR 3,609 billion, up 6.5% year-over-year; EBITDA grew 0.1% to IDR 1,192 billion (35.2% margin).
Gross profit for the period was Rp1,236,162 million, up from Rp1,191,768 million year-over-year.
PAT and PATMI declined by 12.2% and 13.8%, respectively; earnings per share was Rp12.62, down from Rp15.11.
Inpatient revenue rose 11.6% and outpatient revenue grew 1.9% year-over-year for 6M26.
Cash and bank balances at period end were Rp571,787 million as of June 30, 2026.
Outlook and guidance
Plans to roll out six new Centers of Excellence in oncology, cardiac care, stroke, fertility, orthopedics, and uro-nephrology.
Pipeline includes greenfield hospital development in Kepanjen (100 beds, opening 3Q26) and brownfield expansions in Lampung, Arcamanik, and Bogor.
Hospital management services (PT MLM) are expanding as a profit center, serving both internal and external hospitals.
Management continues to focus on maintaining healthy capital structure and compliance with loan covenants.
The Group plans to increase share capital to support future liquidity and growth.
Latest events from PT Medikaloka Hermina
- Q1 2026 net revenues rose 5.4% to Rp1,783.2 billion, with net income at Rp132.3 billion.HEAL
Q1 2026 - FY25 revenue rose 6.2% to IDR 7,134 billion, with prudent leverage and BPJS revenue flagged as a risk.HEAL
Q4 2025 - Revenue up 5.2% in 9M25, net income down, with new hospitals opening in 4Q25.HEAL
Q3 2025 - Strong revenue and profit growth, robust expansion, and solid capital structure maintained.HEAL
Q2 2024 - Revenue and net income surged in 9M24, supported by expansion and strong financials.HEAL
Q3 2024 - Double-digit revenue and profit growth, strong margins, and continued network expansion.HEAL
Q4 2024 - Revenue and profit declined, but equity, investments, and credit rating remain strong.HEAL
Q1 2025 - Net income and margins fell despite higher revenue and asset growth in 6M25.HEAL
Q2 2025